Mechanism of Hepatocyte Transduction by AAV Vectors
Mechanism of Hepatocyte Transduction by AAV Vectors
批准号:
7489003
负责人:
Arun Srivastava
金额:
$6.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2010-07-31
关键词:
AccountingAdenovirusesAttentionCell CommunicationDNADNA biosynthesisDNA chemical synthesisDNA-PKcsDataDependovirusDevelopmentEnzymesEvaluationExcisionFailureFrequenciesGenomeGlycogen Storage DiseaseHandHepatocyteHumanIn VitroInfectionInjection of therapeutic agentKnock-outKnockout MiceKnowledgeLeadLife Cycle StagesLightLiverLiver diseasesMediatingMolecularMusPP5 protein-serine-threonine phosphatasePhosphoric Monoester HydrolasesPhosphotransferasesProtein C InhibitorProtein DephosphorylationProtein OverexpressionProtein phosphataseProteinsRateRecombinant adeno-associated virus (rAAV)Research PersonnelRetroviridaeRoleSerineSingle-Stranded DNAT-cell protein tyrosine phosphataseTailTechniquesTestingThreonineTransgenic MiceTransgenic OrganismsTyrosineVeinsViralViral Genomealpha 1-Antitrypsin Deficiencybaseexpression vectorgene therapyimprovedin vivomouse modelnovel strategiesprogramstacrolimus binding protein 4transduction efficiencytransgene expressionvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The adeno-associated virus 2 (AAV) vectors have gained attention as an alternative to the more commonly used retrovirus- and adenovirus-based vectors. Recombinant AAV vectors have been shown to target the liver efficiently, but the transgene expression is restricted to approximately 5% of the hepatocytes. Because the viral genome is a single-stranded DNA,
and single strands of both polarities are encapsidated with equal frequency, it has been suggested that failure to undergo DNA strand-annealing accounts for the lack of efficient transgene expression. Others and we, on the other hand, have proposed that failure to undergo viral second-strand DNA synthesis contributes to the observed low efficiency of transgene expression. We have previously documented that a cellular protein, designated FKBP52, inhibits AAV second-strand DNA synthesis, when present in phosphorylated forms, and consequently, limits transgene expression in non-hepatic cells, whereas unphosphorylated forms of FKBP52 have no effect. To further evaluate whether phosphorylated FKBP52 is also involved in regulating AAV-mediated transgene expression in murine hepatocytes, we generated transgenic mice over-expressing the cellular T cell protein tyrosine phosphatase (TC-PTP) protein, known to catalyze dephosphorylation of FKBP52, as well as mice deficient in FKBP52. We have demonstrated that dephosphorylation of FKBP52 in TC-PTP transgenic (TC-PTP-TG) mice, and removal of FKBP52 in FKBP52-knockout (FKBP52-KO) mice, results in efficient transduction of murine hepatocytes following tail-vein injection of recombinant AAV vectors. We have also documented efficient viral second-strand DNA synthesis in hepatocytes from both TC-PTP-TG and FKBP52-KO mice. Thus, our data strongly support the contention that the viral
second-strand DNA synthesis, rather than DNA strand-annealing, is the rate-limiting step in the efficient transduction of hepatocytes. This proposal will test the following hypotheses: 1. FKBP52 is phosphorylated at serine/threonine residues by DNA-PKcs, and dephosphorylated by PP5; 2. Optimal transduction of primary hepatocytes is limited by serine/threonine phosphorylated forms of FKBP52, but can be overcome by deliberate overexpression of PP5; 3. DNA-PKcs-deficient mice overexpressing TC-PTP allow efficient transduction of murine hepatocytes; and 4. Efficient integration of the AAV proviral genome occurs in primary hepatocytes in DNA-PKcs-deficient/ TC-PTP-transgenic mice in vivo. The knowledge gained from these studies will not only shed light on the AAV-hepatocyte interactions, but will also be applicable in further improvements in recombinant AAV vectors for their potential use in gene therapy of human liver diseases in general, and al-antitrypsin deficiency (AATD) and glycogen storage disease (GSD) in particular, the main focus of this PPG application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AAV2 and hepatocellular carcinoma
-
批准号:9528459
-
项目类别:
-
资助金额:$18.47万
-
财政年份:2017
-
负责人:Arun Srivastava
-
依托单位:
Mechanism of Hepatocyte Transduction by AAV Vectors
-
批准号:7017369
-
项目类别:
-
资助金额:$21.1万
-
财政年份:2005
-
负责人:Arun Srivastava
-
依托单位:
Human Parvovirus B19 Vectors: Mechanism of Transduction
-
批准号:7024569
-
项目类别:
-
资助金额:$35.52万
-
财政年份:2004
-
负责人:Arun Srivastava
-
依托单位:
Human Parvovirus B19 Vectors: Mechanism of Transduction
-
批准号:6855770
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2004
-
负责人:Arun Srivastava
-
依托单位:
Human Parvovirus B19 Vectors: Mechanism of Transduction
-
批准号:7391091
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2004
-
负责人:Arun Srivastava
-
依托单位:
Human Parvovirus B19 Vectors: Mechanism of Transduction
-
批准号:7178444
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2004
-
负责人:Arun Srivastava
-
依托单位:
Human Parvovirus B19 Vectors: Mechanism of Transduction
-
批准号:6927575
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2004
-
负责人:Arun Srivastava
-
依托单位:
Hematepoietic Stem Cell Transduction by AAV2 Vectors
-
批准号:6337984
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2001
-
负责人:Arun Srivastava
-
依托单位:
Hematepoietic Stem Cell Transduction by AAV2 Vectors
-
批准号:6746916
-
项目类别:
-
资助金额:$18.23万
-
财政年份:2001
-
负责人:Arun Srivastava
-
依托单位:
Hematepoietic Stem Cell Transduction by AAV2 Vectors
-
批准号:6638693
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2001
-
负责人:Arun Srivastava
-
依托单位:
Hematepoietic Stem Cell Transduction by AAV2 Vectors
-
批准号:6989486
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2001
-
负责人:Arun Srivastava
-
依托单位:
Hematepoietic Stem Cell Transduction by AAV2 Vectors
-
批准号:6537874
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2001
-
负责人:Arun Srivastava
-
依托单位:
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES
-
批准号:2799137
-
项目类别:
-
资助金额:$18.8万
-
财政年份:1999
-
负责人:Arun Srivastava
-
依托单位:
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES
-
批准号:6139109
-
项目类别:
-
资助金额:$19.22万
-
财政年份:1999
-
负责人:Arun Srivastava
-
依托单位:
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES
-
批准号:6612874
-
项目类别:
-
资助金额:$25.75万
-
财政年份:1999
-
负责人:Arun Srivastava
-
依托单位:
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES
-
批准号:6343470
-
项目类别:
-
资助金额:$23.16万
-
财政年份:1999
-
负责人:Arun Srivastava
-
依托单位:
BASIC SCIENCE STUDIES ON GENE THERAPY OF BLOOD DISEASES
-
批准号:6490682
-
项目类别:
-
资助金额:$22.61万
-
财政年份:1999
-
负责人:Arun Srivastava
-
依托单位:
AAV-MEDIATED TRANSDUCTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
-
批准号:6105677
-
项目类别:
-
资助金额:$12.08万
-
财政年份:1998
-
负责人:Arun Srivastava
-
依托单位:
ADENO ASSOCIATED VIRUS MEDIATED TRANSDUCTION--HEMATOPOIETIC STEM/PROGENITOR CELLS
-
批准号:6110408
-
项目类别:
-
资助金额:$20.42万
-
财政年份:1998
-
负责人:Arun Srivastava
-
依托单位:
PARVOVIRUS VECTORS FOR HUMAN GENE THERAPY
-
批准号:6043991
-
项目类别:
-
资助金额:$40.15万
-
财政年份:1997
-
负责人:Arun Srivastava
-
依托单位:
海外基金